A key symptom of Huntington's disease (HD), irritability contributes to a decline in functioning and to great distress in both patients and their caregivers. To identify mutation carriers prone to the development of irritability, this study aimed to investigate the course and temporal relationships between irritability and other neuropsychiatric symptoms. A cohort of 90 mutation carriers was followed for two years. Using the Irritability Scale, the incidence of irritability was 23% whereas irritability persisted in 70%. An increase in irritability was strongly associated with an increase in apathy. 35 
aBstraCt
A key symptom of Huntington's disease (HD), irritability contributes to a decline in functioning and to great distress in both patients and their caregivers. To identify mutation carriers prone to the development of irritability, this study aimed to investigate the course and temporal relationships between irritability and other neuropsychiatric symptoms. A cohort of 90 mutation carriers was followed for two years. Using the Irritability Scale, the incidence of irritability was 23% whereas irritability persisted in 70%. An increase in irritability was strongly associated with an increase in apathy.
IntroduCtIon
Neuropsychiatric symptoms, motor disturbances, and cognitive impairment are core symptoms of Huntington's disease (HD) {1-3}, an autosomal dominant, neurodegenerative disorder resulting from an expanded trinucleotide cytosine-adenine-guanine (CAG) repeat in the HTT gene on chromosome 4 that codes for the mutant protein huntingtin. Although under normal circumstances huntingtin is present ubiquitously, its physiologic role is not fully elucidated. The mutant huntingtin probably confers a toxic gain of function, mainly resulting in striatal cell loss.
The age of onset is widespread, ranging from early childhood to senescence, and is generally about 40 years. The duration between diagnosis of motor symptoms and death is around 20 years.
Neuropsychiatric symptoms, such as irritability, apathy and depressed mood often precede the onset of motor symptoms.
Irritability is a common and key neuropsychiatric symptom of HD {4-6}, which can be characterized as a mood state predisposing towards anger, hostile appraisals, impatience, intolerance, poorly controlled anger and overt aggression {7;8}. Reduced control over temper frequently occurs, resulting in verbal or behavioral outbursts. However, irritability may also be present without observable manifestation. Irritability should be distinguished from the DSM-IV-TR diagnosis of intermittent explosive disorder, since the latter has to meet strict, observable criteria and is severe in its phenotype and consequences, whereas irritability may not even be visible to an observer. The subjective experience of irritability may be either brief or prolonged.
In contrast to justifiable anger, verbal or behavioral outbursts originating from irritable mood are nonadaptive, complicate the interaction between the patient and his environment, and are always unpleasant for the individual. Irritability can occur early in the course of HD, e.g. up to 10 years before the onset of motor symptoms {9} and often contributes to a decline in personal and occupational functioning {10}. Moreover, irritability of mutation carriers may also cause great distress among others, affecting the wellbeing of their families and possibly contributing to the necessity of institutionalization {11}.
The prevalence of irritability ranges from 35% to 73%, depending on its definition, the assessment tools used, and the study populations {2;9;12}. In REGISTRY (a European multi-center prospective observational study including both manifest and premanifest HD mutation carriers) a prevalence of 19.1% of overt disruptive or aggressive behavior among was found among 1468 mutation carriers {13}. Two prospective studies conducted among 12 pre-motorsymptomat-ic{14}-and 111 motorsymptomatic{15} HD mutation carriers showed that irritability increased over time.
Cross-sectional studies of irritability in motor-symptomatic mutation carriers have found associations with other neuropsychiatric symptoms including impulsivity{4}, obsessive compulsive symptoms{16} and suicidal thoughts{17}. Using the 14-item Irritability Scale{18;19}, we earlier demonstrated an association between irritability and a low Total Functioning Capacity (TFC) score, use of benzodiazepines and more often being married or living together{2}.
Since irritability can occur before the onset of motor symptoms, our cohort included both pre-motor symptomatic and motor symptomatic mutation carriers. Although cross-sectional associations with irritability have been investigated before {2;4;16;17}, to our knowledge, this is the first study investigating predictors of incident and persistence of irritability in HD, also this is the first study investigating correlates of change in irritability over time. Identification of mutation carriers prone to the development and persistence of irritability is required to provide adequate treatment and support of HD mutation carriers and their families. Therefore, this study investigates the course and temporal relationships between irritability and other neuropsychiatric symptoms in a cohort of 90 HD mutation carriers followed for two years.
methods

Participants
HD mutation carriers and first-degree non-carriers were recruited between May 2004 and August 2006 from the outpatient departments of Neurology and Clinical Genetics of Leiden University Medical Centre (LUMC) and from a regional nursing home specialized in HD. All participants underwent genetic testing and were considered HD mutation carriers with a CAG repeat length ≥ 36 repeats. A second measurement was conducted 2 years after the first measurement and a third measurement 2 years thereafter. The study design has been described in detail elsewhere{20}.
In the present longitudinal analysis, only the data of mutation carriers who participated in the second and third waves of this study are included, because the Irritability Scale {2} was introduced halfway during the first measurement. Here, the second wave is referred to as the 'baseline measurement' and the third wave as the 'follow-up measurement' . A total of 121 mutation carriers completed the Irritability Scale at baseline and irritability was also assessed in 90 mutation carriers at follow-up. In total 32 mutation carriers dropped-out ( Figure 1 ).
The study was approved by the medical ethical committee of the LUMC and informed consent was obtained from all participants.
Instruments
Assessment of irritability
Irritability was assessed with the self-rated Irritability Scale (Appendix I) that consists of 14 questions addressing the presence of various phenomena of irritability in the two weeks prior to the interview, rated on a 4-point Likert scale {18}. The total sum score of the Irritability Scale ranges from 0 -42 points with higher scores indicating more severe irritability. We used a cut-off score of > 13 points as indicative for the presence of irritability; this score was selected based on our previous cross-sectional study among 130 HD mutation carriers (largely overlapping with baseline data of the current study) where this cut-off provided optimal sensitivity and speci-ficity according to ROC analyses {2}. The Cronbach's alpha of the irritability scale is 0.90 and its sensitivity and specificity for detecting irritability in HD mutation carriers is 0.69 and 0.81, respectively {2}. We preferred the use of the Irritability Scale over the PBA irritability subscale because the Irritability Scale was designed specifically for the assessment of irritability in neurodegenerative disease. Also, the psychometric properties of the Irritability Scale are better than those of the PBA irritability subscale (Crohnbachs alpha of 0.90 vs. 0.67, respectively). Since no cut-off score for the PBA irritability subscale for the presence of irritability exists, a direct comparison is not possible. In our previous study however, we found that with a cut-off score on the PBA irritability factor of >15 points, a cut-off score of >13 point on the irritability score yielded a sensitivity of 0.69 and a specificity of 0.81.
Assessment of other neuropsychiatric characteristics
The Problem Behaviors Assessment (PBA) was used to assess depression. The PBA is a semistructured interview assessing the frequency and severity of 36 potential behavioral problems in HD in the month before the interview {4}. The interrater reliability of the Dutch version of the PBA is 0.82 for severity scores and 0.73 for frequency scores. We used the symptom factor depression (range 0-80) that was previously estimated by factor analysis of the PBA {5}. Apathy was different features of apathy in the 2 weeks before the interview. Caregivers' information and the interviewers' judgment was included in rating the Apathy Scale, since patients with apathy may lack adequate insight into their own symptoms. The Apathy Scale was chosen above the apathy factor of the PBA because, although no clear preference arises from the literature, the Apathy Scale has better psychometric properties than the PBA apathy subscale (Crohnbach's alpha 0.89 vs. 0.84, respectively) and because the former was specifically designed for the assessment of apathy.
Sociodemographic and clinical characteristics
Information on sociodemographic and clinical characteristics (including alcohol consumption, use of psychotropic medication and information about the household) was collected in a standard- 
Statistical analyses
Data are presented as n (%), mean (± standard deviation; S.D.) or median (inter-quartile range;
IQR) when appropriate. Associations between sociodemographic-, clinical-and neuropsychiatric characteristics on the one hand, and incident and persistent irritability on the other were determined using univariate logistic regression; odds ratios (ORs) were computed for the incidence or persistence of irritability. For the assessment of incident irritability, we identified HD mutation carriers without irritability at baseline who were irritable at follow-up. Similarly, for the assessment of persistent irritability we identified HD mutation carriers who were irritable at baseline and remained irritable at follow-up. A multivariate logistic regression (adjusting for sex and age that were entered into the model) was conducted with variables with p < 0. Of the 57 non-irritable HD mutation carriers at baseline, the 13 mutation carriers with incident irritability at follow-up had, at baseline, a longer mean CAG repeat length, a higher UHDRS-m score, , a lower MMSE score, lower scores on all executive cognitive measures including the ExCog variable, and more frequently used benzodiazepines, compared with HD mutation carriers who did not develop irritability. In a logistic regression models adjusting for sex and age, a longer CAG repeat length, a higher UHDRS-m score, a higher use of benzodiazepines, , a lower MMSE score and worse cognitive functioning at baseline were all associated with incident irritability at follow-up. (Table 1 ) Next, we built a final multivariate logistic model adjusting for all these significant correlates. In this model, all determinants lost their significance. (Table 1 ).
There were no significant differences in mutation carriers who showed remission of irritability compared to those with persistent ( Table 2 ). In the final model, we adjusted for the use of antidepressants, SDMT score and Stroop color score, since these variables had a correlation with a p-value<0,10 in the univariate analyses. In this model, there were no significant associations. We analyzed the association between changes in the clinical and neuropsychiatric characteristics with the change in Irritability Scale score. In univariate analyses of these changes, we found that an increase in UHDRS-m score, an increase in the Apathy Scale and the use of both antipsychotics and of benzodiazepines were associated with an increase in the Irritability Scale score over time. Next, we built a final multivariate regression model, comprising sex and age at baseline, increase in UHDRS-m score, Apathy Scale score, and the change in use of both antipsychotics and of benzodiazepines. We found that the association between change in Irritability Scale score and change in Apathy Scale score persisted after adjustment for confounders ( Figure 2 ). Furthermore the continuous use of antipsychotics was independently associated with an increase in Irritability Scale score. Beta and 95% confidence interval (CI) derived from linear regression with change in irritability score between baseline and follow-up as dependent variable. *Fully adjusted model is also adjusted for increase in motor score, use of benzodiazepines and use of antipsychotics.
dIsCussIon
In this study, we investigated the course of irritability and its associations with clinical and neuropsychiatric symptoms in a cohort of 90 HD mutation carriers who were followed for 2 years.
An increasing severity of apathy and the continuous use of antipsychotics were associated with increasing severity of irritability over 2 years.
A recent longitudinal study of neuropsychiatric symptoms followed 111 HD patients for a mean of 5 years {15}. At five moments of assessment during follow-up, a minimum of 49% of HD patients had one or more symptom of irritability and a maximum of 83% had one or more symptom of irritability. However, the proportions of any of these symptoms cannot be translated easily into a prevalence rate of the syndrome of irritability which we used in out analyses. Therefore, our incidence of 23% may be a good representation of new-onset irritability at 2-year follow-up in individuals with HD.
We found a link between apathy and irritability in HD, reflected by our finding that an increase in apathy coincided with an increase in irritability over a 2-year period. At first glance this may seem paradoxical. Apathy is a disorder of motivation that is mainly characterized by a lack of goal-directed behavior and cognition and by decreased emotional responsiveness. On the other hand, irritability has been characterized as a mood state predisposing toward negative or hostile appraisals and to the experience of anger. Although irritability may lead to the overt expression of anger, it may also only bother the patient himself without overt expression of irritability. In this paradigm, an individual with apathy may well experience irritability, a hypothesis which is supported by our study. An explanation for this comorbidity of apathy and irritability in HD may be that they have a related pathophysiology since both are caused by neural degeneration in subcortical and frontal circuits{28;29}, which is a key feature of HD, in particular the anterior cingulate cortex (ACC) and the orbitofrontal cortex (OFC). The ACC plays an important role in affect-regulation{30} as well as in decision making{31}. Lesions in the ACC, or in neuronal circuitry connected to it, have been associated with apathy{28} as well as behavioral inhibition, and aggression{28}. The orbitofrontal cortex is involved in impulse inhibition and lesions in the area of the OFC are associated with behavioral disinhibition and emotional lability {28}. In addition, hypoactivation of the OFC, as well as the ACC, is associated with impulsive aggression {29}. Although emotional lability and impulsive aggression may be components of overt, observable irritability, these symptoms are absent in irritability that remains out of awareness and to our knowledge, the role of subcortical circuitry has not been investigated in this type of irritability. Therefore, the comorbidity of apathy and irritability may only be partly due to a related pathophysiology. Another factor to be considered is the possibility between construct overlap of irritability and apathy as measured by the Irritability and the Apathy Scales respectively. When looking at the items of both scales, there are no obvious similarities or overlapping items. Using Spearman's correlation analyses, we found that the largest correlation coefficient was 0,44 between any of the 14 items of the Irritability scale and any of the 14 items of the Apathy Scale. This rather low correlation on any two single items suggest that phenomenological or scale reasons cannot account for the associations we found over time between irritability and apathy .
We found an association between the use of antipsychotics and increasing irritability. Although selective serotonin reuptake inhibitors are recommended as a first-step treatment, antipsychotics are frequently prescribed for irritability and related behaviors {32}. Several underlying mechanisms may explain the association between the used of antipsychotics and irritability. On the one hand, antipsychotics may have been prescribed to treat (among others) irritability, likely resulting in confounding by indication as the treated group may on average still be more irritable than the untreated group. On the other hand, antipsychotics may have caused irritability or some other third factor may underlie the relationship. Furthermore, in some patients antipsychotics (both first-generation and second-generation) are known to cause akathisia, a state of psychomotor agitation{33}. Patients experiencing psychomotor agitation associated with akathisia, may either become irritable or may have reported positively on certain items on the Irritability Scale due to some overlap between the two constructs.
We assessed irritability using the Irritability Scale because this scale was used to assess irritability in our earlier cross-sectional study{2}. On this scale, our previously validated cut-off score of 14 points for the presence of irritability enabled us to investigate the occurrence and correlates of incident and persistent irritability.
The strengths of this study are its prospective design, a relatively large cohort of HD mutation carriers, and the use of validated instruments for the assessments of determinants and outcomes. A few limitations should also be addressed. First, although we have validated the use of the Irritability Scale in our previous study, there is no gold standard for the assessment of irritability. Second, a relatively high number of mutation carriers dropped-out and, therefore, did not participate in the current analysis; irritability at follow-up may have been a reason not to participate. Selection bias may account for an underestimation of the incidence of irritability and for the underestimation of the predictive value of some predictors because of insufficient power. Third, we cannot exclude the possibility that cognitive dysfunction in our HD patients has distorted the reliability and sensitivity of scales that assessed of neuropsychiatric characteristics.
In conclusion, we found an unexpected association between irritability and apathy. HD mutation carriers that become more apathetic over time also seem to become more irritable.
The association between irritability and apathy may imply a shared underlying pathophysiology between these neuropsychiatric symptoms in HD. Since apathy may mask irritability, we recommend asking mutation carriers with apathy and their caregivers about the symptoms of irritability in order to provide adequate support and treatment.
